<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189420</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 58310716.6.0000.5461</org_study_id>
    <nct_id>NCT03189420</nct_id>
  </id_info>
  <brief_title>Glioma Microenvironment an Exploratory Study</brief_title>
  <official_title>Glioma Microenvironment an Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Sirio-Libanes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffuse glioms are primary brain tumors characterized by infiltrative growth and high
      heterogeneity, which render the disease mostly incurable. Advances in genetic analysis
      revealed that molecular and epigenetic alterations predict patients´s overall survival and
      clinical outcome. However, glioma tumorigenicity is not exclusively caused by its genetic
      alterations. The crosstalk between tumor cells and the surrounding microenvironment plays a
      crucial role in modulating glioma growth and aggressiveness. In this sense, to understand the
      tumor microenvironment would elucidate potential treatment alternatives. The focus will be to
      evaluate myeloid cells and cytokines levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal is to study gene expression and early epigenetic changes in myeloid cells from
      brain tumors and co-culture experiments. Tough RNA-seq, ATAC-seg and subsequent analysis to
      monitor the differential gene expression through different time points followed by stimuli.
      The study will compare the obtained results with sequencing data from microglia of
      full-fledged human tumor samples (glioblastoma and low grade gliomas). Additionally it will
      evaluated the immunologic characteristic of the tumor through cytokines levels analysis
      (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-13, IFN-γ, TGF-β e IL-1ra).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>gene expression changes</measure>
    <time_frame>2 years</time_frame>
    <description>Though RNA-seq, ATAC-seg and subsequent analysis we will be able to monitor the differential gene expression through different time points followed by stimuli.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokines expression</measure>
    <time_frame>2 years</time_frame>
    <description>will evaluate the immunologic characteristic of the tumor through cytokines levels analysis (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-13, IFN-γ, TGF-β e IL-1ra).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioma of Brain</condition>
  <arm_group>
    <arm_group_label>Glioblastoma</arm_group_label>
    <description>Samples of brain tumor diagnosed as glioblastoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low grade glioma</arm_group_label>
    <description>Samples of brain tumor diagnosed as low grade glioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor resection</intervention_name>
    <description>The tumors will be resected in routine therapeutic surgeries</description>
    <arm_group_label>Glioblastoma</arm_group_label>
    <arm_group_label>Low grade glioma</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged between 18-65 years old diagnosed with glioblastoma or low grade glioma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 65 years old with brain tumor

          -  Patients that will be submitted to brain tumor ressection

        Exclusion Criteria:

          -  Chronic neurodegenerative and inflamatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>São Paulo</city>
        <state>Sao</state>
        <zip>01308060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Martinez, PhD</last_name>
      <phone>+551133944779</phone>
      <email>quelmartinez@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Komori T. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8.</citation>
    <PMID>28592714</PMID>
  </reference>
  <reference>
    <citation>Galatro TF, Vainchtein ID, Brouwer N, Boddeke EWGM, Eggen BJL. Isolation of Microglia and Immune Infiltrates from Mouse and Primate Central Nervous System. Methods Mol Biol. 2017;1559:333-342. doi: 10.1007/978-1-4939-6786-5_23.</citation>
    <PMID>28063055</PMID>
  </reference>
  <reference>
    <citation>Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017 Mar 13;31(3):326-341. doi: 10.1016/j.ccell.2017.02.009. Review.</citation>
    <PMID>28292436</PMID>
  </reference>
  <reference>
    <citation>Chiorean R, Berindan-Neagoe I, Braicu C, Florian IS, Leucuta D, Crisan D, Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data. Cancer Biomark. 2014;14(2-3):185-94. doi: 10.3233/CBM-130310.</citation>
    <PMID>24878820</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sirio-Libanes</investigator_affiliation>
    <investigator_full_name>Raquel Chacon Ruiz Martinez</investigator_full_name>
    <investigator_title>Principal investigator, PhD</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>low grade tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

